Company Research Report: Symbiosis Pharmaceutical Services

Company Overview

Name: Symbiosis Pharmaceutical Services

Mission: The company's mission is to accelerate clients’ drug development timelines by offering rapid access to sterile fill-finish manufacturing slots and product release services.

Founded: Symbiosis was established in 2011.

Founders: No information is available.

Key People:

• CEO: Colin MacKay

Headquarters:

• Scion House, Stirling Innovation Park, Stirling, FK9 4NF, Scotland, UK.

• 2nd Floor, 625 Massachusetts Ave, Cambridge, MA 02139, USA.

Number of Employees: The company will safeguard over 130 skilled life sciences jobs and create an additional 50 new jobs as part of their expansion plans.

Revenue: No information is available.

Company Known For: Symbiosis is known for specializing in the cGMP manufacture of conventional and biological pharmaceuticals, providing aseptic manufacturing services, and offering fill-finish expertise for complex drug products.

Products

Offered Products and Services:
1. mAbs and Recombinant Therapies: Extensive experience in delivering hundreds of projects and supporting clinical trials.

2. Small Molecule Manufacturing: GMP manufacturing across a wide range of small molecule applications, including highly potent materials requiring specialist handling.

3. Vaccines Manufacturing: Supporting clinical batches across attenuated or inactivated products to recombinant, viral vector, and nucleic acid-based vaccine technologies.

4. ATMPs/Viral Vector Therapies: Manufacturing of viral vectors for cell and gene therapies, oncolytic viruses, and critical raw materials such as plasmids.

5. RNA and Peptide Therapies: Support with challenging manufacturing and handling requirements that need specialist knowledge and experience.

6. Antibody-Drug Conjugates (ADC): Manufacturing capabilities for highly potent ADCs.

7. Sterile Fill Finish/Aseptic Filling: Fully licensed for sterile filling of liquid and lyophilised products.

8. Product Development Services: Assistance with product development to bring products from pre-clinical phases into clinical trials.

9. Bulk Lyophilisation: Integration of lyophilisation or gas overlay as part of the aseptic filling process.

10. QP Release and Clinical Label/Pack Services: Certification of clinical and commercial batches and automated labelling and packaging services for drug products.

Key Features of Products:

• Rapid access to GMP sterile fill-finish manufacturing slots.

• Expertise in handling advanced therapeutics like viral vectors and antibody drug conjugates.

• A range of validated delivery options for drug products.

Recent Developments

Recent Developments Include:

• October 10, 2024: Acquisition of a new manufacturing facility financed by Barclays Corporate Bank PLC, aimed at increasing high-tech manufacturing capabilities. The new 20,000 sq/ft facility at the Castle Business Park in Stirling will strengthen GMP manufacturing capacity by 50% in the short term and create 50 new jobs.

• August 30, 2024: Scottish Enterprise celebrated record results for the Scottish economy during a visit to Symbiosis. Symbiosis received a £4.3 million grant to accelerate growth, creating 50 new jobs.

• August 5, 2024: Released an infographic for optimizing freeze/thaw for gene therapy production.

• January 16, 2024: Strengthening of the commercial team in the United States with the appointment of Lee-Jay Strifler as a Business Development Manager to support West Coast biotech and biopharma clients.

• December 20, 2023: Hosted a webinar discussing the impact of Annex 1 on aseptic manufacturing processes.

• November 21, 2023: Granted an MHRA license following a £1M investment in new in-house analytical and microbiological capabilities.

New Products and Features:

• Introduction of new cleanroom-based production lines to support biotechnology and pharmaceutical clients.

• Expansion to facilitate manufacturing of a range of medicines, including anti-cancer drugs and advanced gene therapy products.

New Partnerships/Collaborations:

• Partnership with Barclays Corporate Bank PLC for financing new facility acquisition.

• Continued collaboration with Scottish Enterprise, which provided grants to support growth and expansion.

Contact Information

• Address:

• Scion House, Stirling Innovation Park, Stirling, FK9 4NF, Scotland, UK.

• 2nd Floor, 625 Massachusetts Ave, Cambridge, MA 02139, USA.

• Phone: +44 (0) 1786 220 000

• Email: contact@symbiosis-pharma.com

The report above outlines the available details and highlights the strategic growth and recent achievements of Symbiosis Pharmaceutical Services.